Results 251 to 260 of about 73,942 (286)

Multi‐omics profiling of chronic immune‐mediated skin diseases: SKINERGY protocol and strategic evaluation

Journal of the European Academy of Dermatology and Venereology, EarlyView.
The SKINERGY study will investigate six immune‐mediated inflammatory skin diseases through a nationwide collaboration across all Dutch university medical centres. Involving 720 patients and 120 healthy volunteers, it is aimed at generating a high‐quality dataset to identify biomarkers that enable personalized treatment strategies and improved disease ...
N. G. Koster, J. M. P. A. van den Reek, E. M. G. J. de Jong, S. van Beugen, A. I. M. van Laarhoven, I. Haeck, M. de Bruin‐Weller, M. L. Schuttelaar, B. Horvath, A. Gostyński, A. Knulst, M. H. Vermeer, L. Nguyen, L. Gerbens, P. Spuls, M. A. Middelkamp‐Hup, V. Exadaktylos, T. Niemeyer‐van der Kolk, A. R. Schrader, A. M. Sluijmers, J. Versteeg, B. W. M. Arents, I. van Ee, J. L. A. G. van der Zon, M. de Leeuw, T. de Leeuw, P. van den Broek, C. Berkhof, D. Vellinga, S. Weidinger, S. Dubrac, Y. Li, M. van Steensel, M. Marchetti‐Deschmann, M. Maurer, H. van der Zee, J. Damman, D. J. Hijnen, F. Wijk, M. M. B. Seyger, H. Röckmann, D. M. W. Balak, M. B. A. van Doorn, R. Rissmann, The Next Generation ImmunoDermatology (NGID) consortium, Rob Vreeken, Eva Cuypers, Boudewijn Lelieveldt, Abdoel El Ghalbzouri, Hanna Niehues, Ellen van den Bogaard, Tom Ederveen, Els van der Pool, Nanda Olde, Debra Trampe, Ellen Stijl‐’t Hart, Lisanne Wezendonk, Johan Westerhuis, Huma Shehwana, Joerg Schreiber, Jeremy Bost, Mie Bech Lukassen, Jimmy Bakker, Juliette Simons, Fauve van den Berge, Colin Spence, Elise Beljaards, Anastasiia Myronenko, Mariona Oliver   +68 more
wiley   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Pharmacophore and docking-based virtual screening approach for the design of new dual inhibitors of Janus kinase 1 and Janus kinase 2

SAR and QSAR in Environmental Research, 2014
Janus kinase 1 and 2, non-receptor protein tyrosine kinases, are implicated in various cancerous diseases. Involvement of these two enzymes in the pathways that stimulate cell proliferation in cancerous conditions makes them potential therapeutic targets for designing new dual-targeted agents for the treatment of cancer.
Haneesh Jasuja, Om Silakari
exaly   +3 more sources

Molecular cloning and functional characterization of duck Janus kinase 1

Molecular Immunology, 2020
Janus kinase 1 (JAK1) is a member of JAK family of non-receptor protein tyrosine kinases that plays critical roles in transducing cytokine signals via JAK-signal transducer and activator of transcription (STAT) signaling pathway. The importance of JAK1 in innate immunity has been well-studied in mammals and fish, yet in avian remains largely unknown ...
Dejian, Liu, Huijun, Zheng, Yaqian, Li, Peng, Zhou, Hui, Jin, Rui, Luo   +5 more
openaire   +2 more sources

Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib

Journal of the American Academy of Dermatology, 2017
BACKGROUND: Existing therapies for vitiligo are limited in efficacy and can be associated with undesirable side effects. Topical Janus kinase inhibitors may offer a new therapeutic option for vitiligo.
Brooke E Rothstein, Deep Joshipura, Rana Abdat   +2 more
exaly   +2 more sources

Mechanism of Janus kinase 3-catalyzed phosphorylation of a Janus kinase 1 activation loop peptide

Archives of Biochemistry and Biophysics, 2003
A high-affinity IL-2 receptor requires two Janus protein tyrosine kinases (JAKs) for IL-2 signal transduction: JAK1 and JAK3. Since transphosphorylation of the two kinases is presumed to occur after receptor engagement we examined the phosphorylation by recombinant JAK3 of a peptide substrate corresponding to the JAK1 activation loop (KAIETDKEYYTVKD ...
Ruixiu, Wang, Patrick R, Griffin, Eliza C, Small, James E, Thompson   +3 more
openaire   +2 more sources

Novel triazolo-pyrrolopyridines as inhibitors of Janus kinase 1

Bioorganic & Medicinal Chemistry Letters, 2013
The identification of a novel fused triazolo-pyrrolopyridine scaffold, optimized derivatives of which display nanomolar inhibition of Janus kinase 1, is described. Prototypical example 3 demonstrated lower cell potency shift, better permeability in cells and higher oral exposure in rat than the corresponding, previously reported, imidazo ...
Christopher A, Hurley, Wade S, Blair, Richard J, Bull, Christine, Chang, Peter H, Crackett, Gauri, Deshmukh, Hazel J, Dyke, Rina, Fong, Nico, Ghilardi, Paul, Gibbons, Peter R, Hewitt, Adam, Johnson, Tony, Johnson, Jane R, Kenny, Pawan Bir, Kohli, Janusz J, Kulagowski, Marya, Liimatta, Patrick J, Lupardus, Robert J, Maxey, Rohan, Mendonca, Raman, Narukulla, Rebecca, Pulk, Savita, Ubhayakar, Anne, van Abbema, Stuart I, Ward, Bohdan, Waszkowycz, Mark, Zak   +26 more
openaire   +2 more sources

Piceatannol, a metabolite of resveratrol, attenuates atopic dermatitis by targeting Janus kinase 1

Phytomedicine, 2022
Piceatannol is a resveratrol metabolite commonly found in red wine, grapes. Several studies have investigated the immune-modulating effects of piceatannol on processes related to allergic reactions. However, the relationship between piceatannol and atopic dermatitis (AD) has not yet been reported.
Chang Hyung Lee, Hee Yang, Jung Han Yoon Park, Jong-Eun Kim, Ki Won Lee   +4 more
openaire   +2 more sources

TREX‐1 related Aicardi‐Goutières syndrome improved by Janus kinase inhibitor

American Journal of Medical Genetics Part A, 2023
AbstractAicardi‐Goutières syndrome (AGS) is a genetic interferonopathy classically characterized by early onset of severe neurologic injury with basal ganglia calcifications, white matter abnormalities, and progressive cerebral atrophy, along with lymphocytosis and raised interferon alpha (INFα) in the cerebrospinal fluid (CSF).
Claire Ryckmans, Mylène Donge, Antonia Marchèse, Meriem Mastouri, Caroline Thomee, Katrien Stouffs, Sandra‐Lucile Lieser, Emmanuel Scalais   +7 more
openaire   +2 more sources

Phosphorylation-Induced Conformational Dynamics and Inhibition of Janus Kinase 1 by Suppressors of Cytokine Signaling 1

The Journal of Physical Chemistry B, 2022
The dysfunction of the JAK/STAT (Janus kinase/signal transducers and activators of transcription) pathway results in several pathophysiological conditions, including autoimmune disorders. The negative feedback regulators of the JAK/STAT signaling pathway, suppressors of cytokine signaling (SOCS), act as a natural inhibitor of JAK and inhibit aberrant ...
Md Fulbabu Sk, Nisha Amarnath Jonniya, Rajarshi Roy, Parimal Kar   +3 more
openaire   +2 more sources

A noncanonical role for Janus kinase 1 in lymphoma

Science Signaling, 2016
JAK1-dependent chromatin phosphorylation promotes the survival of aggressive lymphoma cells.
openaire   +1 more source